酮替芬联合氯雷他定治疗小儿咳嗽变异性哮喘的临床效果探讨  

Discussion on the clinical effect of ketotifen and loratadine in the treatment of cough variant asthma in children

作　　者：沈磊 于萍[1] 朱琳[1] SHEN Lei;YU Ping;ZHU Lin(Department of Pediatrics,Dalian Central Hospital,Dalian 116033,China)

机构地区：[1]大连市中心医院儿科,116033

出　　处：《中国实用医药》2021年第25期111-113,共3页China Practical Medicine

摘　　要：目的探讨小儿咳嗽变异性哮喘治疗中应用酮替芬联合氯雷他定的临床效果。方法90例小儿咳嗽变异性哮喘患儿作为研究对象,以奇偶数列法为原则分为参照组和实验组,每组45例。参照组患儿采用酮替芬治疗,实验组在参照组基础上采用氯雷他定治疗。对比两组患儿治疗前后肺通气功能指标[用力肺活量占预计值的百分比(FVC%)、第一秒用力呼气容积(FEV1)、最大呼气流量占预计值的百分比(PEF%)],治疗前后炎性因子[C反应蛋白(CRP)、转化生长因子β1(TGF-β1)]水平,临床治疗效果,用药不良反应发生情况。结果治疗前,两组患儿FVC%、FEV1、PEF%比较差异无统计学意义(P>0.05);治疗后,两组患儿FVC%、FEV1、PEF%水平均明显高于治疗前,且实验组显著高于参照组,差异具有统计学意义(P<0.05)。治疗前,两组患儿CRP、TGF-β1水平比较差异无统计学意义(P>0.05);治疗后,两组患儿CRP、TGF-β1水平均明显低于治疗前,且实验组低于参照组,差异具有统计学意义(P<0.05)。实验组患儿总有效率95.56%(43/45)高于参照组的80.00%(36/45),差异具有统计学意义(χ^(2)=5.075,P=0.024<0.05)。两组患儿的用药不良反应发生率比较差异无统计学意义(χ^(2)=0.155,P=0.694>0.05)。结论小儿咳嗽变异性哮喘患儿采用酮替芬联合氯雷他定治疗,能提升肺通气功能,改善治疗效果,值得进一步借鉴应用。Objective To discuss the clinical effect of ketotifen and loratadine in the treatment of cough variant asthma in children.Methods A total of 90 children with cough variant asthma as study subjects were divided into a reference group and an experimental group according to odd even column method,with 45 cases in each group.The reference group was treated with ketotifen,and the experimental group was treated with loratadine on the basis of the reference group.The pulmonary ventilation function indexes[forced vital capacity as a percentage of predicted value(FVC%),forced expiratory volume in the 1st second(FEV1),peak expiratory flow as a percentage of expected value(PEF%)],levels of inflammatory factors[C-reactive protein(CRP),transforming growth factor-β1(TGF-β1)]before and after treatment,clinical effect,and occurrence of adverse drug reactions were compared between the two groups.Results Before treatment,there was no statistically significant difference in FVC%,FEV1 and PEF%between the two groups(P>0.05).Before treatment,the FVC%,FEV1 and PEF%of the two groups were obviously higher than those before treatment,and experimental group was significantly higher than the reference group.All the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in levels of CRP and TGF-β1(P>0.05).After treatment,the levels of CRP and TGF-β1 of the two groups were obviously lower than those before treatment,and the experimental group was lower than the reference group.All the difference was statistically significant(P<0.05).The total effective rate of the experimental group was 95.56%(43/45),which was higher than 80.00%(36/45)of the reference group,and the difference was statistically significant(χ^(2)=5.075,P=0.024<0.05).There was no statistically significant difference in incidence of adverse drug reactions between the two groups(χ^(2)=0.155,P=0.694>0.05).Conclusion Combination of ketotifen combined with loratadine for children with cough variant asthma can improve

关 键 词：酮替芬 氯雷他定 小儿咳嗽变异性哮喘 

分 类 号：R725.6[医药卫生—儿科]